Antineoplastic Agents, Immunological
"Antineoplastic Agents, Immunological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000074322
|
| MeSH Number(s) |
D27.505.954.248.384
|
| Concept/Terms |
Antineoplastics, Monoclonal Antibodies- Antineoplastics, Monoclonal Antibodies
- Antibodies Antineoplastics, Monoclonal
- Monoclonal Antibodies Antineoplastics
- Monoclonal Antibodies, Antineoplastic
- Antineoplastic Monoclonal Antibodies
- Antineoplastic MAbs
- Antineoplastics, Monoclonal Antibody
- Monoclonal Antibody Antineoplastics
- MAbs, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Immunological".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Immunological".
This graph shows the total number of publications written about "Antineoplastic Agents, Immunological" by people in this website by year, and whether "Antineoplastic Agents, Immunological" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 1 | 2 |
| 2017 | 7 | 1 | 8 |
| 2018 | 20 | 4 | 24 |
| 2019 | 10 | 3 | 13 |
| 2020 | 13 | 6 | 19 |
| 2021 | 7 | 6 | 13 |
| 2022 | 3 | 1 | 4 |
| 2023 | 3 | 0 | 3 |
| 2024 | 3 | 4 | 7 |
| 2025 | 5 | 0 | 5 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.
-
Durable stable disease and immune activation in metastatic uveal melanoma treated with tebentafusp: case report. Front Immunol. 2026; 17:1864115.
-
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors. J Immunother Cancer. 2026 Jun 24; 14(6).
-
Biomarker study of pembrolizumab in patients with advanced rare cancers. Cell Rep Med. 2026 Jun 16; 7(6):102827.
-
Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 12; 23(12).
-
Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non-Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score-Matched Analysis. JCO Glob Oncol. 2025 03; 11:e2400256.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
-
Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study. Cancer Chemother Pharmacol. 2025 Mar 21; 95(1):46.
-
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
-
HER2-Positive Breast Cancer Treatment and Resistance. Adv Exp Med Biol. 2025; 1464:495-525.
-
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.